Ze Jing Pharmaceuticals (688266.SH): The new drug application for treatment of severe alopecia areata with Gicasitimetine hydrochloride tablets has been accepted for review.

The Wise Finance APP news, Zejin Pharmaceuticals (688266.SH) announced that on May 12, 2025, the company received the "Acceptance Notice" issued by the National Medical Products Administration. The company's new drug application (NDA) for hydrochloride Jigasixuni tablets for the treatment of severe alopecia areata was accepted for review. This is the second indication for which hydrochloride Jigasixuni tablets have applied for new drug approval.